Ellen Lubman

Ellen is Chief Business Officer of Impel Neuropharma, a private neuroscience therapeutics company, where she leads corporate development activities and strategy. Prior to joining Impel, she served as the Vice President of External Science & Innovation at Allergan, where she was responsible for strategic expansion of the company’s pipeline in a variety of disease areas, including women’s health.

Ellen has 20 years of biopharmaceutical corporate development and Wall Street industry experience, including roles at Kadmon Pharmaceuticals, Bristol-Myers Squibb, Celtic Pharma Management, L.P., and Robertson Stephens.

She is a member of the Board of Directors of Dauntless Pharmaceuticals and GeneCentric Therapeutics.